April 21, 2021Open Access

Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

LAM-cell/fibroblast interactions attract mast cells where tryptase release contributes to disease progression. Repurposing SCG for use in LAM should be studied as an alternative or adjunct to mTOR inhibitor therapy.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Babaei‐Jadidi et al. (Wed,) studied this question.

synapsesocial.com/papers/6a02a28ec8c4199b329e2430 https://doi.org/https://doi.org/10.1164/rccm.202007-2854oc

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Lymphatic Endothelial Differentiation in Pulmonary Lymphangioleiomyomatosis Cells2013 · 24 citations
2Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases2019 · 377 citations
3Lymphangioleiomyoma Cells and Lymphatic Endothelial Cells2010 · 10 citations
4Possible involvement of mast cells in collagen remodeling in the late phase of cutaneous wound healing in mice2004 · 134 citations
5Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9–mediated progenitor cell mobilization2005 · 227 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo